TY - JOUR
T1 - The effect of platelet-rich plasma on female androgenetic alopecia
T2 - A randomized controlled trial
AU - Dubin, Danielle P.
AU - Lin, Matthew J.
AU - Leight, Hayley M.
AU - Farberg, Aaron S.
AU - Torbeck, Richard L.
AU - Burton, William B.
AU - Khorasani, Hooman
N1 - Publisher Copyright:
© 2020 American Academy of Dermatology, Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Background: Platelet-rich plasma (PRP) may be a useful treatment for androgenetic alopecia (AGA), although objective studies are needed. Objective: To determine whether PRP injections improve female AGA. Method: Prospective randomized controlled trial of 30 women diagnosed with AGA. Patients received subdermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4, and 8. Outcome measures were changes in hair density (hair/cm2), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24. Results: Blinded global photographic assessment indicated that 57% of patients receiving PRP versus 7% of patients receiving saline improved at week 24 from baseline (P < .01). Compared to baseline, there was improvement in mean density in the PRP group versus the placebo group at week 8 (+71.1 vs −26.7 hairs/cm2; P < .01) and week 24 (+105.9 vs −52.4 hairs/cm2; P < .01). Compared to baseline, there was improvement in mean caliber in the PRP group versus the placebo group at week 8 (+0.0043 vs −0.0034 mm; P < .01) and week 24 (+0.0053 vs −0.0060 mm; P < .01). Adverse effects included headache, scalp tightness, swelling, redness, and postinjection bleeding. Limitations: Two patients lost to follow-up. Conclusions: PRP with the Eclipse system is a safe and effective intervention for female AGA.
AB - Background: Platelet-rich plasma (PRP) may be a useful treatment for androgenetic alopecia (AGA), although objective studies are needed. Objective: To determine whether PRP injections improve female AGA. Method: Prospective randomized controlled trial of 30 women diagnosed with AGA. Patients received subdermal scalp injections of Eclipse system PRP or placebo saline at weeks 0, 4, and 8. Outcome measures were changes in hair density (hair/cm2), hair caliber (mm), and blinded global photographic assessment (improved or not improved) at week 24. Results: Blinded global photographic assessment indicated that 57% of patients receiving PRP versus 7% of patients receiving saline improved at week 24 from baseline (P < .01). Compared to baseline, there was improvement in mean density in the PRP group versus the placebo group at week 8 (+71.1 vs −26.7 hairs/cm2; P < .01) and week 24 (+105.9 vs −52.4 hairs/cm2; P < .01). Compared to baseline, there was improvement in mean caliber in the PRP group versus the placebo group at week 8 (+0.0043 vs −0.0034 mm; P < .01) and week 24 (+0.0053 vs −0.0060 mm; P < .01). Adverse effects included headache, scalp tightness, swelling, redness, and postinjection bleeding. Limitations: Two patients lost to follow-up. Conclusions: PRP with the Eclipse system is a safe and effective intervention for female AGA.
KW - androgenetic alopecia
KW - female pattern hair loss
KW - platelet-rich plasma
KW - regenerative medicine
UR - http://www.scopus.com/inward/record.url?scp=85090440147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090440147&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.06.1021
DO - 10.1016/j.jaad.2020.06.1021
M3 - Article
C2 - 32649961
AN - SCOPUS:85090440147
SN - 0190-9622
VL - 83
SP - 1294
EP - 1297
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 5
ER -